

# Press Release



ASKA Pharmaceutical Holdings Co., Ltd.

## Notice regarding Booking of Gain on Sales of Investment Securities (Extraordinary Income)

---

**TOKYO, September 25, 2023** – ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi) announced that the Company expects to record the following gain on sales of investment securities as a result of the partial sale of investment securities held by the Company's subsidiary, ASKA Pharmaceutical Co., Ltd.

### 1. Reason for sale

To ensure effective use of the assets held by the Company.

### 2. Details of the sale

(1) Shares to be sold: Six listed securities

(2) Method of sale: Market sale

(3) Sale period: Second quarter of the fiscal year ending in March 2024

(4) Gain on sales of investment securities: 2,200 million yen (estimate)

The above is an estimated amount calculated based on the current stock prices of the relevant securities and is subject to change depending on market conditions.

### 3. Future outlook

The Company plans to sell the above investment securities and two other securities in the third quarter of FY2023. It expects to record a gain on sales of investment securities of 2,700 million yen for FY2023, including 64 million yen recorded up to the first quarter of FY2023.

The impact of this matter on the Company's business performance for FY2023 has already been incorporated in the "Notice of Revisions to the Forecast of Consolidated Financial Results for FY2023" released today.

---

### Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: [kouhou@aska-pharma.co.jp](mailto:kouhou@aska-pharma.co.jp)